Objectives. This study examiaed the toa@em~ ~.montb) ef.
long4enn beta.blockadel. In an elegBnl bU1 uaonlrollcd study of buciodolol on myoeardii performance, Eiihbom et al. (5) concluded that after 3 months of therapy, improved perfw mallcc was the result of an improvemat in myocaidii contraclility without an increaSe in myocardiat oxygen demand.
Taken together. these studies suggest that long-term treatment with a beta-blocking drug with vasodilating prop erties may improve cardiac performance lhrough a paradoxic improvement in czmtractility. However, because of the reluctance of many practitioners IO initiate a potentially deleterious form of treatment in patients with cardiomyopathy, we thoughf ic worlhwhile to combine the separale strengths of these two studies in a comprehcosive invcsligation of the new beta-blocking agent (RSSS + SRRR)liminobis(methylene~lbis16_Ruorc-3,4-ZH-l-~naopy~n~2~ methaooll-HCCnebivoloCin &ems with cardiomvooathv. a hemodynamic profile qualitatively resembling that of atenolol(8): the nonbeta-blocking Gamer, io contrast to both o-nebivolol and atenolol, decreases peripheral resistance after intravenous injection in dogs by at unexplained mech&w that does not appear to be mediated by any kooown receptor (9). Bacemic nebivolol also reduces oaioheral resistance in humans after oral adminisuation attd'a n&tinvasive index of left ventricular performance is improved (10). Nebivdol has little if any alpha-adrenetgic antagonistic effects (IO) and is devoid of intrinsic sympathcmimetic activity (II).
Our pmtocol was randomized, double-blind and included exercise testing, measurement of plasma biochemical variables, including catecholamines at baseline attd after 3 months, 24-h invasive hemodyoamic monitoring and invasive as-~essntent of I& ventricular wall stress and contractility in an attempt to separate the effects of load and conttactility on ptfomtance.
Methods

Sludy de+.
The protocol was approved by the Ethics Committee of the University of Witwatersnnd
and Bangwmath Hospital. After an explanation of the protocol in his or her own language, each patient gave informed amsent before study enhy. The study war double-blind. randomized and placebo-controlled with two parallel arms. Randomization block size was four. The placebo ruwin phase wa I month and the randomized pb~ was 12 weeks. Twelve patients were initially randomized to each gmup. However. four patients randot&& to nebiidd therapy failed to complete the pm@ cd: one died, two were withdrawn because of newly diagnosed or worsening diabetes mellitus and one defaulted fw social reasons. The latter three patients. who either were withdrawn w defaulted, were repl&ed by an additional three patients withat the randomized tratment b&w divutped to the investigators. Thus, II patients in the neb&lol &I completed the pmtwxi. Cl&e patient in the placebo group defaulted for social reasons. This patient was inadvellentiy rephced with 2 patients: thus, 13 patients completed the placebo arm of the study. Hemodynamic assessment petformed at the end of the nut-in phase included 12 h of hewdynamic monitoring with Swan-Ganz catheters before radomiration and. at 4 h after placebo administration. I& heart cathetetization with left ventticular cineangiography. The 24-h hemaiytwic study and attgiqmphic assessment were repeated at the end of the randomized phase. Two exercise tests (modified Naugbton pmtocd) were petfomted during the nut-in phase at weekly intervals, again weekly during the Meek titration phase, at week 6 and ftnally at comple%n of the trial.
Rtkmt sckctim. Eligibility criteria were I) age ~18 and ~6.5 years, 2) stable New York Heart Associa!ion functional class II oc III congestive heart failure an diuretic therapy fl&osemide). 31 svstolic left ventricular dvsfunction (eiec-iionfraetio~~.~5 tb0.4Obygated radionucli&angiogra&L 4) abiiity to perform treadmill exercise for a4 and 512 min using a modiied Nau&ton protocol, and 5) reproducible Characteristics of the patients enrolled are shown in Table 1 . Cornnary angiagraphy revealed severe tw* and three-vessel disease sunmestive of an ischemic ori& in two patients (nebivolol Gp) and minor (GO% n&rowing) disease in four others (three in the nebivolol group and one in the olacelm aowL No other soecific etiolties for heart failure were id~nti&d and. an the basis of the exclusion criteria, no patient was thought to have a predomioantly hypertensive origin of heart failure. All patients were native Africans. hup titaim. After the ha@& hemodynamic study, patients were randomized to receive nebivolol (I @day) or placebo. The drug dose was increased at weekly intervals over the next 2 weeks to 2.5 and 5 mg if well tolerated. AU patients were maintained on fimsemide plus pMassium supplementation.
Hemcdyxmmic and angi~apbic stud&es. Twelve-hour monitoring with Swa&anz catheters was performed hourly at the end of the run-in phase and for 24 h again (hourly for 12 hand then once every 3 h for 12 h) at the completion of the trial. TO ensure stability, catheters were inserted though the subclavian or jugular vein on the evening before the monitoring period began; patients fasted during this time. Pulmonary wedge pressure and cardiac output measuremoots were repeated until ~10% variation was observed between two consecutive meas"rements before drugs were administered. During the baseline study, left heart catheterization with left ventricular tine-and conmar, angiography were performed 4 h after hemodynamic monitoring was initiated and placebo was given because this is the time estimated to reach peak effect for nebivolol. During the final period of hemodynamic monitoring, left heart satheterization and I& ventricular cineangiography were again performed at 4 h after drug (nebivolol or placebo) was given. The femoral armroach with local anesthesia onlv was used. Left ventt'icul~~ pressure was measured with & 8F micromanometer pigtail catheter. Biplane left ventricular cineanglography was performed with 40 to 50 ml of sodium meglumine ioxaglate.
Methods used for analysis of the left ventricular pressure aad simultaneous angiographic volume data, and estimation of contractile function using the preload-corrected ejection fraction (EE!-end svstolic stress (ES9 relations have been described ihdetail (i2). The p&ndic&r distance of data for each individual patient from the previous1y published regression line of a normal control group (12) was comwted as: PESS x sine(arctangent[regression slope]), where hESS is the horizontal distance from the preload.corrected ejection fraction-end-systolic stress coordinate to the regression line. This is a modification of the method of Lang et al. (13), who used the vertical distance at a common end-systolic stress. Diastolic pressure-volume data were not considered adequate for estimation of preload-corrected ejection fraction in one patient in the nebivolol group and in one patient in the placebo group at baseline study and another at 3 months. All angiographic analyses were performed in a blinded fashion before the drug codes wew broken. Pressure-volume loops were con&ted from digitized micromanometer left ventricular oressore (not smoothed) and from frame by frame angiographic (area-length) volomb time data smoothed with a 10th.order polynomial equation using a Marquardt curve-fitting program. 5iocbemicl studies. Plasma norepincphrine analysis was performed by using high performance liquid chromatography; blood samples were immediately put on ice after they were drawn. Routine biochemistry studies were performed with standard technique.
.Stat&s. Two-way analysis of variance was used to assess ditTerent responses between the nebivolol and placebo groups.
Drugdosinga~~I&Iee&ts~
Themaximaldoseofdmgwas reachedin7oFlIpatientsrandomLedtonebivololand llof13 randomized to placeb+ therapy. Medication compliaoce determined by pill cwnt was >% in all but two patients (85% e~nplianeebyeaeh)inthenebivddgmupand>%inallbut one patient (7% compliance) in the placebo group.
Two patients initially randomized to nebivolol were withdrawn before completion of the protocol because of new or worsening diabetes (see Methods). There was one sudden death in the mhivolol group. Of the II patients who completed the nebivolol arm of the protocol. one complained of mental depression but did not have to be withdrawn fmm the study. In the remaining patients, side etiect protiles were low. with no admissions for worsening heart failure. Exe&e time. There was no signii?cant change in evercise duration in either group, nor was there any difference between the groups at baseline (554 + 70 s at baseline to 536 f 83 s at 3 months for the mbivolol group sod 492 + I21 s to 570 + 105 8 for the placebo group). Peak systolic blood pressure in the nebivolol groop was I50 1 24 mm Hg at baseline aad 145 + 22 mm Hg at 3 months (p = NS): maximal heart rate was 140 + 12 beatslmin at baseline and decreased to I20 f 22 beatdmin at 5 months (p = 0.005). In the placebo gmup, the correspandiog exercise vuiabies were 160+19mmHgvel3us158~25mmHgat3monulsand 143 * 22 beats/min to 147 f 21 bcatslmin @ = NS for both).
Hnnodrpunka (Tabk 2, Fii. 1). Twelve-and 24-h invasive monitoring showed that only heart rate and stroke sow and pulmonary artery pressure were not significantly differcat from those in the placebo group. The only hemodynamic deterioration in the oebivolol group was as follows: one patient bad a sigoiiicant decline (defined as a 20% decrease fmm the baseline value) in cardiac output without a significant chaoge in wedge pressure, and one patient had a sigoificant increase in wedge pressure without a significant change in cardii output. Neither of these patients had to be withdrawn from the study because of side effects. Similar mcasurcments were obtained for both groups in the catheterization laboratorv ITable 3). Analvsis of hieh lid&v measurements of lek &ic& p&are in the"ttebivol~l group showed a denease in IeR ventricular end-diastolic prcssurc but no change in the maximal rate of prcssttre development (dP/dt_) or in either measured variable of left venttictdar relaxation (maximal negative first derivative of left ventricular pressure [-dP/dt_l or time constant IW).
Artgiographll data flMk4, fig. 2 ). Despite adccrcase in heart rate with nebivolol, there was a sliabt decrease in left ventricular enddias!olic volume (p = 6): left venrriculw mass was also decreased at 3 months compared with the baseline mra~uremeot (p = 0.01). End-systdic u&m-c dccreased even though there was no sigaifieant decline in afterload measured eitbw as systemic vascular resistatw or end-systolic stress. The net result was a sigairicant increase in ejection fraction, presumably due to an increasc in myo. cardial contractibty. This finding was corroborated by an increase in the relation of prcload-corrected ejection fraction (EF,) to end-systolic strcs (Fig. 3 ). An exam& of a pressure-volume loop before and 3 months after iebivolol administration is shown io Fiure 4. The reoroducibilitv of the angiographic data is supp&ed by the c&c corrclaiion between left ventricular rcass al baseline and at 3 mooths in the placebo group (Fig. 5) .
Biibcmiml data. Despite high dose dixctic tttempy (mean dose of furosemide at baseline and 3 months I60 and 176 mg in the nebivdol group and 178 and 200 mg in the placebo group. respectively), blood urea and creatinine did not increase and there were no chaws in scntm potassium. sodium or mttgnesium. Flasma twepittcphtiae levels tended to decrease in the ttebivolol group (819 2 M to 5% r 419 pmol!liter) and IO itw-case in the placebo gmap (555 i 376 to 972 .? 271 pawHiter). but the difference was not statistically significant.
Di8m88ion
Comparison with pwiom &dies. Ooe previous study (5) has shown that long-term beta-blockade may improve hernodynamics (l-7) in cardiomyopathy throw& a long-term increase in myoeardial contractility. This is ao intriguing
Table 4. Elects of Nebivolol Versus Pl~ceho on Left Ventricular Volume and Stress
posribili(y because the short-term administration of betablockers produces a negative inotropic effecl. Although that study included elegant measurement of ventricular performance (E,,.), it was not placebo controlled. Recatw of our interest in confirming such a mechanism of action in a placebo-controlled study and because of the reluctance of many to use a potentially deleterious therapy in patients with heart failure. the present detailed investigation was performed. Our results confim, those of Eichhom et al. (5) . who showed that hemodynamic improvement oec"rs through a" improvement in contractile perforntanee and not simply because of a change in heart rate or loading conditions. Several strengths in our study design lend credibility to this seemingly paradoxic conclusion that long-term treatment with a beta-blocker improves depressed contractility in cardiomyopa:hy. First, the addition of a placebo control group ensures that improvement in the treatment group was not spontaneous, as may occur with some types of cardiomyopathy (14): Hemodynamic status and left ventricular size and function were remarkably stable over the 3.mo"th . Finally, both bocindolol and nebivolol are thought to have vasodilating progenies and we considered it importam to assess long-term druge6ects on end-systolic stress to ensure that improvement in ejection fraction war not a result of reduced wall stress. The similarity of baseline and 3-month end-systolic stress in both treatment arms of our study stren&"s lhis condasio" and wmbomtes otu estimate df contractiliw 112). which is otherwise own to criticism.
Contrrchk & i~*utlw h?em. it is noteworthy tbal in 19 of 22 patients with cardiomyopathy in the present rludv. the oreload-corrected eieclion fractio"-end-systolic st&relaiibn, our index of co&actile function, was~below the 95% prediction band defined by a previously studied (12) contmi group. This finding sumests that our index is indeed gnsitive lo chronically depressed contractile state, and it has previously been shown to be relatively load independent (12): Although we could not detect a"; increase in peak positive dl'ldt, this index of contractility decreases with decreasing preload (16). and the decrease in preload observed in OUT patients may have been responsible for "egating the expected increase in peak positive dP/dt.
In contrast to the study of bucindolol of Eichhom et al. (5). we were not able to demonstrate any improvement in variables of mvofardial relaxation ("oak neeative dP/dt and the time constant mu). Whether this diiTerence betweeo studies is due to a difference in drug properties or simply a methodologic difference is not apparent. Nevertheless, Flguw 3. A, Contmtility ertimated as pretuad-corrected ejection fraction (EFJ versus &dead (end-systolic stress [ESSll before and afier nebivold. There is a marked shitl reward the normal regression line by a nriln of tO.12 unit (from -0.36 i 0.13 to -0.24 + 0. IS et 3 months) for the IO patients in whom adequate data were avaikbk. 8. Nochange inertknted contractility &the placebo group Ithal is, the mean prpendicular distance te the EF,-ESS regrersien tine [-0.29 f 0.14 to -029 2 0.14 unit at 3 monthsjj. nebivolol signilicantly reduced lefi ventricular end-diastolic pressure, presumably as a result of the improvement in systolic performance.
Exercke tderanee. Exercise tolerance did not improve with treatment, an e&t that may in part be due to the 20.beat/rein decrease in maximal heat? rate with nebivolol. In the few previous studies of beta-blockade for cardiomyopathy, the effect cm exercise tolerance has differed. Curie et al. (17) dial energetics may play a role. It is also possible that beta-blockade reduces the toxic effects (21) of high cat* cholamine levels (22) on the myacardium. Increased betareceptor density has also been proposed (23). but it is unclear how this would improve contractility ifthe receptors are pharmacologically blocked.
Drug safety. Long-term treatment with phosphodiesterase inhibitors, which have a short-term positive inotropic effect, is poorly tolerated and increases the incidence of death (24). In contrast, beta-blockade given in gradually increasing doses has been well tolerated in patients with cardiomyopathy and, in the few previous studies that included a control group (6.7,18), no deaths were attributable to treatment. There was one death in the nebivolol arm ofthe present study. Ischemia or a malignant arrhythmia, or both, probably accounted for this sudden death and, in v!c'u of the results of the Beta-Blocker Heart Attack Trial (2% it is wlikely that treatment with nebivolol played a causal role. Larger studies are needed to confirm the role of betablockade in reducing malignant arrhythmias and mortality in patients with dilated cardiomyopathy (3).
Llmitallons of the study. First, the small size ofthis study probably prevented us from documenting more significant improvement in hemodynamic variables. Second, estimation of contractile performance is a limitation with the present or any other index of contractility. However, an increase in ejection fraction despite a reduction in preload (end-diastolic pressure and volume) and no change in afte+xtd (endsystolic stress) is difficult to exolain bv any mechanism other than an increase in contm~tile~perfo~man.
Conclusions. Nebivolol is well tolerated with few side effects in patients with cardiomyopathy who are in stable condition and who are on high dose diuretic therapy. With longterm treatment, the drug has a negative chronotropic effect hut paradoxically a positive inotropic effect, which results in a favorable hemodynamic response with an increase in stroke volume and a reduction in left ventriadar filling pressure. Finally, despite hemodynamic improvement. exercise tolerance does not improve.
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